Investigation of HER-2 expression and its Correlation with clinicopathological parameters and overall survival of esophageal squamous cell carcinoma patients

Publish Year: 1399
نوع سند: مقاله ژورنالی
زبان: English
View: 221

This Paper With 8 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

این Paper در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_IJP-15-4_004

تاریخ نمایه سازی: 26 آذر 1399

Abstract:

Background & Objective: Human epidermal growth factor receptor 2 (HER-2) exhibits a vast range of expression in esophageal squamous cell carcinoma (ESCC) patients as a biomarker. This paper aimed to investigate HER-2 expression and clinicopathological parameters of esophageal SCC. Methods: HER-2 expression was assessed in 102 ESCC patients by immunohistochemistry. The HER-2 staining intensity , according to the Gastric HER2 Biomarker1.0.0.1 version of the college of American pathologists (CAP) protocol for gastric and gastroesophageal junction cancers, was graded as 0 (no reactivity in any of the cancer cells’ membranes); 1+ (pale or hardly noticeable reactivity in the membrane of cancer cells’ cluster [≥ 5 neoplastic cells] regardless of the positive cancer cells’ percentage); 2+ (weak-to-moderate complete, basolateral, or lateral membranous reactivity regardless of the positive cancer cells’ percentage); and 3+ ( strong complete, basolateral, or lateral reactivity in the membrane of the cancer cell cluster regardless of the positive cancer cells’ percentage).In this regard, 3+ scored samples were considered as positive. If HER-2 expression was scored 2+, an additional fluorescence in situ hybridization (FISH) was performed. Fisher's exact test was employed for investigating the correlation of HER-2 expression status with patients’ clinicopathological characteristics (including age, gender, tumor location, stage, grade, infiltration level, venous invasion, lymphatic invasion, and tumor recurrence). Kaplan-Meier analysis was done for the patients’ survival assessments. Result: Five patients (~5%) were HER-2 positive and no significant association was observed between HER-2 expression and clinicopathological properties. In addition, HER-2 expression status exhibited no significant association with the patients’ overall survival (p =0.9299).  Conclusion: HER-2 is not a suitable prognostic biomarker for Iranian ESCC patients.

Authors

Mitra Heidarpour

Department of Pathology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Mehran Taheri

Department of Pathology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Ali Akhavan

Department of Radiation Oncology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Parvin Goli

Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Amirhosein Kefayat

Department of Oncology, Cancer Prevention Research Center, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Klingelhöfer D, Zhu Y, Braun M, Brüggmann D, Schöffel N, ...
  • Vijayan K, Eslick GD. Epidemiology and Risk Factors for Esophageal ...
  • Dietz HC. TGF-β in the pathogenesis and prevention of disease: ...
  • Ilson DH. Esophageal cancer chemotherapy: recent advances. Gastrointest Cancer Res. ...
  • Bird-Lieberman E, Fitzgerald RJBjoc. Early diagnosis of oesophageal cancer. 2009;101(1):1. ...
  • Matsuda N, Wang X, Lim B, Krishnamurthy S, Alvarez RH, ...
  • Roskoski Jr R. The ErbB/HER receptor protein-tyrosine kinases and cancer. ...
  • Márquez-Garbán DC, Gorrín-Rivas M, Chen HW, Sterling Jr C, Elashoff ...
  • Genc AZ, Koseoglu RD, Arici A, Demir O. HER-2/neu gene ...
  • Chung YW, Kim S, Hong JH, Lee JK, Lee NW, ...
  • Raziee H, Taghizadeh Kermani A, Ghaffarzadegan K, Taghi Shakeri M, ...
  • Sawyers CL. Herceptin: A First Assault on Oncogenes that Launched ...
  • Kuznetsova M, Lopatnikova J, Shevchenko J, Silkov A, Maksyutov A, ...
  • Yadav K, Shimasaki N, Ow SGW, Wong ALA, Lim JSJ, ...
  • Triulzi T, Forte L, Regondi V, Di Modica M, Ghirelli ...
  • Gonzaga IM, Soares-Lima SC, de Santos PT, Blanco TC, de ...
  • Sato-Kuwabara Y, Neves JI, Fregnani JH, Sallum RA, Soares FA. ...
  • Wei Q, Chen L, Sheng L, Nordgren H, Wester K, ...
  • Peng JH, Zhang X, Song JL, Ran L, Luo R, ...
  • Shu S, Iimori M, Nakanishi R, Jogo T, Saeki H, ...
  • Bartley AN, Jessi Christ C, Fitzgibbons P, Hamilton SR, Kakar ...
  • Roskoski Jr RJPr. The ErbB/HER family of protein-tyrosine kinases and ...
  • Cretella D. Combined use of tyrosine kinase inhibitors (TKIs) and ...
  • Jørgensen JT, Nielsen KB, Kjærsgaard G, Jepsen A, Mollerup J. ...
  • Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, ...
  • Liu Q, Borcherding NC, Shao P, Maina PK, Zhang W, ...
  • Shibata W, Kinoshita H, Hikiba Y, Sato T, Ishii Y, ...
  • Lei YY, Huang JY, Zhao QR, Jiang N, Xu HM, ...
  • Luo H, Xu X, Ye M, Sheng B, Zhu X. ...
  • Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 ...
  • Akamatsu M, Matsumoto T, Oka K, Yamasaki S, Sonoue H, ...
  • Mimura K, Kono K, Hanawa M, Mitsui F, Sugai H, ...
  • Zhan N, Dong WG, Tang YF, Wang ZS, Xiong CL. ...
  • Schoppmann SF, Jesch B, Friedrich J, Wrba F, Schultheis A, ...
  • Maruyama T, Mimura K, Sato E, Watanabe M, Mizukami Y, ...
  • Gibault L, Metges JP, Conan-Charlet V, Lozac'h P, Robaszkiewicz M, ...
  • Reichelt U, Duesedau P, Tsourlakis MC, Quaas A, Link BC, ...
  • Wu D, Xu J, Yu G, Zhang B, Wang H, ...
  • Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, ...
  • Huang JX, Zhao K, Lin M, Wang Q, Xiao W, ...
  • Barros-Silva JD, Leitao D, Afonso L, Vieira J, Dinis-Ribeiro M, ...
  • نمایش کامل مراجع